Joshua Frenkel, MD
Ophthalmology · Auburn, WANPI 1356752091
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.7%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by NEW World Medical,inc. at 24.6% of the total. Reporting peaked in 2021 at $4,717 and has fallen 51.8% since, to $2,274 in 2025. Among ophthalmology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 175 payments — averaging $123.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NEW World Medical,inc.$5K
- Rxsight Inc$4K
- Alcon$3K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- AbbVie$2K
- Ivantis, Inc$1K
- plus $4K from 18 others
What the payments were for
- Consulting fees$9,42544%
- Speaking & faculty fees$4,52621%
- Travel & lodging$4172%
- Food & beverage$7,20833%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NEW World Medical,inc. | 13 | $5,314 |
| Rxsight Inc | 10 | $3,702 |
| Alcon | 31 | $3,428 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 17 | $2,034 |
| AbbVie(2 entities) | 30 | $1,716 |
| Ivantis, Inc | 6 | $1,386 |
| Tarsus Pharmaceuticals, Inc. | 10 | $726 |
| Nordic Pharma, Inc. | 1 | $700 |
| Carl Zeiss Meditec, Inc. | 4 | $562 |
| Sight Sciences, Inc. | 4 | $449 |
| Bausch & Lomb Americas Inc. | 8 | $251 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $188 |
| Thea Pharma Inc. | 3 | $155 |
| Ocular Therapeutix, Inc. | 3 | $153 |
| Kala Pharmaceuticals, Inc. | 9 | $146 |
| Dompe US, Inc. | 4 | $125 |
| Staar Surgical Company | 1 | $106 |
| Glaukos Corporation | 3 | $104 |
| Biotissue Holdings Inc. | 4 | $83 |
| Mallinckrodt Hospital Products Inc. | 2 | $68 |
| Carl Zeiss Meditec USA, Inc. | 1 | $67 |
| Oyster Point Pharma, Inc. | 2 | $49 |
| Eyevance Pharmaceuticals LLC | 3 | $41 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ahmed Glaucoma Valve$4,723
- Kahook Dual Blade$4,723
- RXSIGHT CONTACT LENS$3,406
- RXSIGHT INJECTOR CARTRIDGE$3,406
- RXSIGHT INJECTOR HANDPIECE$3,406
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$3,406
- LIGHT ADJUSTABLE LENS (LAL)$3,406
- VYZULTA$1,500
- BEPREVE$1,500
- PROLENSA$1,500
- LOTEMAX$1,500
- Hydrus$1,150
- Centurion$1,050
- Lacrifill$700
- Clareon$553
- VisuMax$521
- XDEMVY$267
- Clearpath$223
- Streamline$223
- OMNI(R) SURGICAL SYSTEM (US)$218
How this compares
$21,576 in reported general payments places this provider in the 95th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 215 | $192,894 |
| Fluorometholone | 302 | $34,073 |
| Cyclosporine | 59 | $28,119 |
| XiidraLifitegrast | 21 | $19,996 |
| Prednisolone Acetate | 365 | $15,258 |
| LumiganBimatoprost | 13 | $9,112 |
| TobradexTobramycin/Dexamethasone | 18 | $4,862 |
| Latanoprost | 354 | $3,552 |
| Ketorolac Tromethamine | 176 | $3,388 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 42 | $3,034 |
| Travoprost | 14 | $2,513 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 166 | $2,061 |
| ErythromycinErythromycin Base | 111 | $1,334 |
| Ofloxacin | 111 | $1,205 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 96 | $1,133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $1,716 | $202,006228 claims |
| Bausch & Lomb Americas Inc.Xiidra | $251 | $19,99621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 428 ophthalmology providers in Washington.
Other ophthalmology in Auburn
- Laura PerimanSeattle$1.7M
- Sheldon CowenSeattle$560K
- Todd SchneidermanSilverdale$200K
- Jennifer ChaoSeattle$188K
- Mark KontosSpokane Valley$175K
- Audrey RostovBellevue$155K
- John SamplesOlympia$115K
- Barbara SmitSpokane$110K
- Debarshi MustafiSeattle$85K
- Michelle CabreraSeattle$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.